Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Neuren Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
ASX:NEU's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Neuren Pharmaceuticals Debt-to-Equity Related Terms
Neuren Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Neuren Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NEU vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Neuren Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (ASX:NEU) has a Debt-to-Equity of 0.00 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Neuren Pharmaceuticals and its competitors. According to the industry distribution chart, Neuren Pharmaceuticals ranks #999999 out of 971 companies in the Biotechnology industry.
Is Neuren Pharmaceuticals' Debt-to-Equity too high?
Neuren Pharmaceuticals' current Debt-to-Equity is 0.00. Based on the distribution chart, Neuren Pharmaceuticals ranks #999999 out of 971 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #999999 out of 971 companies for Debt-to-Equity. This places Neuren Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Neuren Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuren Pharmaceuticals's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.82, compared to a current price of A$22.72 — trading 190.5% above its estimated fair value. The current Debt-to-Equity is 0.00. Neuren Pharmaceuticals' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Debt-to-Equity is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of A$22.72 is trading 190.5% above its estimated GF Value™ of A$7.82.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:NEU:
Debt-to-Equity: 0.00
GF Value™: A$7.82 vs. price of A$22.72 (190.5% above fair value)
No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
48GF Score
Get the complete analysis for ASX:NEU
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NEU has been successfully added to your 
